109347-40-2

Basic information

• Product Name: (3-BROMOPHENYL)ACETALDEHYDE
• Synonyms: (3-BROMOPHENYL)ACETALDEHYDE;2-(3-bromophenyl)acetaldehyde
• CAS NO: 109347-40-2
• Molecular Formula: C₈H₇BrO
• Molecular Weight: 199.05
• Product Categories: Aromatic Aldehydes & Derivatives (substituted);Aldehydes;Phenyls & Phenyl-Het
• Mol File: 109347-40-2.mol
• Article Data: 23

Chemical Properties

• Boiling Point: 267.5 °C at 760 mmHg
• Flash Point: 99.7 °C
• Appearance: /
• Density: 1.466 g/cm³
• Vapor Pressure: 0.00812mmHg at 25°C
• Refractive Index: 1.556
• CAS DataBase Reference: (3-BROMOPHENYL)ACETALDEHYDE(CAS DataBase Reference)
• NIST Chemistry Reference: (3-BROMOPHENYL)ACETALDEHYDE(109347-40-2)
• EPA Substance Registry System: (3-BROMOPHENYL)ACETALDEHYDE(109347-40-2)

Safety Data

• Hazardous Substances Data: 109347-40-2(Hazardous Substances Data)

Usage

General Description

(3-Bromophenyl)acetaldehyde is a chemical compound with the molecular formula C8H7BrO. It is a white to off-white solid with a molecular weight of 211.04 g/mol. (3-Bromophenyl)acetaldehyde is commonly used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. It is also used in the production of organic synthesis and as a building block for the preparation of various derivatives. (3-Bromophenyl)acetaldehyde is known to be an irritant to the skin, eyes, and respiratory system, and it should be handled with proper safety precautions in a well-ventilated area.

InChI:InChI=1/C8H7BrO/c9-8-3-1-2-7(6-8)4-5-10/h1-3,5-6H,4H2

Upstream product

• 1878-67-7 3-Bromophenylacetic acid 
• 2039-86-3 3-bromostyrene 
• 872-36-6 vinylene carbonate 
• 89598-96-9 (3-bromophenyl)boronic acid 
• 28022-44-8 2-(3-bromophenyl)oxirane 
• 98288-51-8 2-(3-bromophenyl)acetyl chloride 
• 28229-69-8 2-(3-bromophenyl)ethan-1-ol 
• 150529-73-0 methyl 2-(3-bromophenyl)acetatee 
• 866270-03-3 2-(3-bromophenyl)-N-methoxy-N-methylacetamide 
• 50-00-0 formaldehyd 
• 306773-37-5 (3-bromobenzylidene)hydrazine 
• 131567-05-0 (S)-(+)-2-(3-bromophenyl)oxirane 

Downstream Products

• 866270-04-4 ethyl 4-(3-bromophenyl)-3-oxobutanoate 
• 1564890-35-2 N¹-(3-bromophenethyl)-N³,N³-dimethylpropane-1,3-diamine 
• 58971-11-2 2-(3-bromophenyl)ethanamine 
• 28229-69-8 2-(3-bromophenyl)ethan-1-ol 
• 660424-25-9 N-[5-(3-bromophenyl)-pyridazin-3-yl]-N-isopropylamine 
• 660424-28-2 N-[5-(3-bromophenyl)-pyridazin-3-yl]-N-ethylamine 
• 660425-13-8 5-(3-bromophenyl)-3-chloropyridazine 
• 660425-12-7 5-(3-bromophenyl)-(2H)-pyridazin-3-one 
• 872018-39-8 (Z)-3-(3-bromophenyl)-2-methylacrylic acid 
• 851678-88-1 (S)-[2-(3-bromo-phenyl)-ethyl]-{1-[6-(tert-butyl-dimethyl-silanyloxymethyl)-pyridin-2-yl]-ethyl}-amine 
• 105512-81-0 2-amino-4-(m-bromophenyl)thiazole 

Relevant articles and documents

Synthesis of Arylacetaldehydes by Iridium-Catalyzed Arylation of Vinylene Carbonate with Arylboronic Acids

The one-step synthesis of arylacetaldehydes by carbon–carbon bond formation between formylmethyl and aryl groups has been realized by the reaction of vinylene carbonate with arylboronic acids in the presence of an iridium/bisphosphine catalyst and a catalytic amount of tetrahydroxydiboron.

C8-substituted pyrido[3,4-d]pyrimidin-4(3H)-ones: Studies towards the identification of potent, cell penetrant Jumonji C domain containing histone lysine demethylase 4 subfamily (KDM4)inhibitors, compound profiling in cell-based target engagement assays

Residues in the histone substrate binding sites that differ between the KDM4 and KDM5 subfamilies were identified. Subsequently, a C8-substituted pyrido[3,4-d]pyrimidin-4(3H)-one series was designed to rationally exploit these residue differences between

Compound with 2-aminopyrimidine structure as well as preparation method and purpose thereof

The invention provides a compound of a 2-aminopyrimidine structure shown as a general formula (1), or a stereisomer, enantiomers or medically acceptable salt of the compound, a preparation method of the compound, a medicine composition containing the composition or a purpose of the composition. The compound shown as the general formula (1) can be used for preparing NIK kinase inhibitors, and can be used for preventing and/or treating diseases relevant to NIK kinase, particularly cancer and metabolic diseases, such as B-cell dysfunction related cancer such as multiple myeloma, lymphocyte carcinoma, diffuse large B cell lymphoma of liver cancer, hodgkin lymphoma and chronic lymphocytic leukemia, prostatic cancer, liver cancer, intestinal cancer, medicine induced liver damage, alcohol inducedliver damage, toxic induced acute liver injury, chronic liver inflammation and the like. The general formula (1) is shown in the description.